A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancerJosé Baselga, Hope S. Rugo, Ahmad Awada et al.|Breast Cancer Research and Treatment|2017Cited by 18